Revolution Medicines, BeOne Medicines form collaboration on RAS cancer drug combinations

• Revolution Medicines entered a multi-part collaboration with BeOne Medicines covering combination trials of BeOne oncology assets with RAS(ON) inhibitors.
• BeOne also secured exclusive regional rights in select Asian markets to develop or commercialize four clinical-stage RAS(ON) inhibitors.
• Revolution is eligible for development and sales milestones, with tiered royalties on net sales in the partnered region.
• Revolution retained rights outside the licensed territory, including Japan and South Korea.
• BeOne will fund and run a global registrational Phase 3 trial for one RAS(ON) inhibitor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.